[BRIEFING.COM] The major averages remain firmly lower, although the health care sector (+1.0%) is once again attracting defensive rotational buying amid the continued weakness in technology stocks.
Regeneron Pharma (REGN 922.63, +103.86, +12.68%) is surging to new 52-week highs after reporting better-than-expected Q3 earnings and revenue, supported by strong Dupixent sales growth and improved collaboration economics with Sanofi (SNY 44.58, +1.45, +3.36%).
Eli Lilly (LLY 1434.94, +61.24, +4.46%) is also extending yesterday's post-earnings rally, providing another source of support for the sector.